Medical Lasers; Engineering, Basic Research, and Clinical Application 2018; 7(1): 47-51  
Treatment of Refractory Rosacea with a Dual Wavelength Long-Pulsed 755-nm Alexandrite and 1,064-nm Nd:YAG Laser
Yoon Jin Choi1, Dae Suk Kim2, Suhyun Cho1
1Yonsei BB Skin Clinic, Seoul, Korea, 2Yonsei Young Skin Clinic, Seoul, Korea
Correspondence to: Suhyun Cho, Yonsei BB Skin Clinic, 551 Siheung-daero, Gurogu, Seoul 08392, Korea, Tel.: +82-2-837-8275, Fax: +82-2-837-8276, E-mail:
Received: June 23, 2018; Accepted: June 25, 2018; Published online: June 30, 2018.
© Korean Society for Laser Medicine and Surgery. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The 755-nm and 1,064-nm lasers, when compared with the 595-nm pulsed dye laser, can provide deeper penetration into the dermis, allowing for targeting of deeper and larger vessels. Photon absorption by hemoglobin at 755-nm is better than that at 1,064-nm; hence, more efficient vascular ablation can be induced when using 755-nm laser. However, 755-nm laser is highly absorbed by melanin, and it should be used in caution considering epidermal damage and threshold fluences for vascular clearance. Microsecond Nd:YAG laser is less painful with good safety profiles compared with the traditional millisecond Nd:YAG laser and pulsed dye laser. Accordingly, the dual wavelength long-pulsed 755-nm alexandrite/microsecond 1,064-nm Nd:YAG laser, together with has both advantages of each laser and can show benefits with complementary, synergistic effects in treating rosacea. Herein, we describe two patients with rosacea who were effectively treated with the dual wavelength long-pulsed 755-nm alexandrite/microsecond 1,064-nm Nd:YAG laser without noticeable side effects.
Keywords: Rosacea; Dual wavelength; Long-pulsed; Alexandrite laser; Nd:YAG laser

This Article